1. Li, Linzhi, Jiang, Pengcheng, Hu, Weimin, Ning, Jinzhuo, Cheng, Fan. 2024. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2. In Journal of translational medicine, 22, 295. doi:10.1186/s12967-024-05099-6. https://pubmed.ncbi.nlm.nih.gov/38515112/
2. Gao, Xiaoyan, Jiang, Aigui, Shen, Yahui, Lu, Huiyu, Chen, Rong. . Expression and clinical significance of AURKB gene in lung adenocarcinoma: Analysis based on the data-mining of bioinformatic database. In Medicine, 100, e26439. doi:10.1097/MD.0000000000026439. https://pubmed.ncbi.nlm.nih.gov/34397793/
3. Joshi, Sunil K, Nechiporuk, Tamilla, Bottomly, Daniel, Druker, Brian J, Traer, Elie. 2021. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. In Cancer cell, 39, 999-1014.e8. doi:10.1016/j.ccell.2021.06.003. https://pubmed.ncbi.nlm.nih.gov/34171263/
4. Zhu, Guoqing, Luo, Laihui, He, Yongzhu, Hu, Zhigao, Shan, Renfeng. 2024. AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway. In Molecular carcinogenesis, 63, 1814-1826. doi:10.1002/mc.23775. https://pubmed.ncbi.nlm.nih.gov/38874176/
5. Tu, Rongfu, Kang, Ye, Pan, Yiwen, Lu, Xinlan, Zhang, Chengsheng. 2024. USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer. In Cancer cell international, 24, 33. doi:10.1186/s12935-024-03224-5. https://pubmed.ncbi.nlm.nih.gov/38233848/
6. Yan, Cheng, Niu, Yandie, Wang, Xuannian. 2022. Blood transcriptome analysis revealed the crosstalk between COVID-19 and HIV. In Frontiers in immunology, 13, 1008653. doi:10.3389/fimmu.2022.1008653. https://pubmed.ncbi.nlm.nih.gov/36389792/
7. Criscione, Steven W, Martin, Matthew J, Oien, Derek B, Yao, Yi, Smith, Paul D. 2022. The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. In NPJ precision oncology, 6, 95. doi:10.1038/s41698-022-00337-w. https://pubmed.ncbi.nlm.nih.gov/36575215/
智鼠故事 
